SEC Tracker
Get the app

Actuate Therapeutics ACTU

Actuate Therapeutics received Nasdaq delisting notice

Nasdaq bid price notice, cure by Apr 26, 2027, Item 3.01 Listing standards notice

Form
8-K
Filed
Importance
Major
  1. Nasdaq notified Actuate Therapeutics of bid price below $1.00 for 30 days
  2. Company has 180 days until April 26, 2027, to regain compliance
  3. Failure to comply could lead to delisting from Nasdaq Global Market

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Actuate Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The notice from Nasdaq does not immediately affect the listing of the company's stock, which continues to trade under the symbol ACTU on the Nasdaq Global Market.
  2. The company has 180 days, until April 26, 2027, to regain compliance with the minimum bid price requirement.
  3. During this time, the stock must close at $1.00 per share for 10 consecutive business days.
  4. If the company fails to regain compliance, it may be eligible for a second 180-day period to meet the requirements if it transfers its listing to the Nasdaq Capital Market.
  5. To qualify, the company must meet the market value and other listing standards for the Nasdaq Capital Market, excluding the minimum bid price requirement.

5 of 6 claims matched the filing text.

Not found in the filing text

  • The filing is numbered 0001683168-26-008193.

From the filing

Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or St

Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.

On October 28, 2026, Actuate Therapeutics, Inc.

(the "Company") received a written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock (the "Common

Stock") had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement").

The Notice has no immediate effect on the listing of the Common Stock1, which continues to trade on The Nasdaq Global Market under the symbol "ACTU". In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until April 26, 2027, to regain compliance with the Minimum Bid Price Requirement2.

To regain compliance, the closing bid price of the Company's Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days3 during the 180-day compliance period ending April 26, 2027, as required under Nasdaq Listing Rule 5810(c)(3)(A), and the Company must otherwise satisfy

The Nasdaq Global Market's requirements for listing.

If the Company does not regain compliance during the compliance period, the Company may be provided a second 180 calendar day period to regain compliance if it applies to transfer the listing of the Company's Common Stock to the Nasdaq Capital Market4. To qualify, the Company must meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market (with the exception of the Minimum Bid Price Requirement)5, based on the Company's most recent public filings and market information and notify Nasdaq of its intent to cure the deficiency. If the Company does not regain compliance within the allotted complianc

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lite Strategy LITS public float $43M, Dec 31, 2025
  2. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025
  3. Fortress Biotech FBIO public float $44M, Jun 30, 2025
  4. CervoMed CRVO public float $40M, Jun 30, 2025
  5. Acumen Pharmaceuticals ABOS public float $45M, Jun 30, 2025